Transaction Report:
(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)
Editor: Andrea Leibfried 1st Editorial Decision 31 March 2015
Thank you for submitting your manuscript entitled 'Crosstalk between Akt/GSK3β signaling and dynamin-1 regulates CME in non-neuronal cells'. I have now received reports of all referees, which are enclosed below.
As you will see, both referees find your work potentially interesting. However, they raise a couple of concerns that need to be addressed. I won't list all concern here, as both reports are clearly written and offer constructive suggestions on how to address the issues raised. Importantly, however, both referees note that the physiological relevance of your conclusions could be better supported. I don't know if you have further data at hand to address this point, but I think adding additional insight into the physiological relevance of dynamin-1 in CME dysregulation would make your paper a truly outstanding one. Referee #2 also requests an ultrastructural phenotypic description of endocytosis in presence of mutant alpha-adaptin. I suggest referring to previous studies for this point.
Given the interest into the topic and the constructive comments provided, I would like to invite you to submit a revised version of the manuscript. Please let me know in case you have further questions regarding the revision. Thank you for the opportunity to consider your work for publication. I am looking forward to receiving your revision! REFEREE REPORTS:
Referee #1: Reis et al report here on the surprising observation that Akt-GSK3beta signaling can activate dynamin 1 in cells lacking the AP-2 alpha ear domain (delta_alphaAD). These have previously been shown to display increased rates of CCP nucleation and fast maturation of a subset of CCPs that compensate for an overall defect in the formation of productive CCPs. The authors report here that dysregulated CME in delta_alphaAD cells is linked to alterations the early endosomal system leading to hyperactive Akt, which via inhibition of GSK3beta appears to release dynamin 1 from phosphoinhibition. Delta_alphaAD cells accumulate APPL1 endosomes close to the plasma membrane resulting in defects in early endosome fusion. Furthermore, the levels of pAkt and its downstream target pGSK3 are upregulated in these cells, a phenotype that depends on the presence of APPL1, a known regulator of endosomal Akt signaling. Reis et al therefore hypothesize that altered Akt-GSK3 affects downstream endocytic or endosomal components, in particular hypophosphorylation and therefore activation of dynamin 1. Finally, it is shown that Tf-CME in wild-type ARPE-19 cells is faciliated by inhibition of GSK3beta, and, importantly this treatment mimicks increased rates of CCP nucleation and altered CCP dynamics observed in delta_alphaAD cells, suggesting that the Akt-GSK3beta pathway may be physiologically regulate CME.
This Ms reveals a potentially interesting connection between CME and Akt signalling that seems worthy of publication in The EMBO J provided my major concerns below have been addressed appropriately.
1. A key conclusion from this work is that dynamin 1 can be activated to support CME in nonneuronal cells; yet, CME remains sensitive to Dyn2 depletion. This is perplexing as the authors note themselves. So, do Dyn1 and 2 operate at the same CCPs and is OE of Dyn2 able to rescue defective CME in Dyn1-depleted delta_alphaAD cells?
2. How do altered distribution of APPL1 endosomes and endosomal defects relate to CME? If indeed altered APPL1 distribution and recruitment and overactivation of Akt is the primary problem then depletion of APPL1 in delta_alphaAD cells should impair CME of Tf, similar to Akt inhibition. This should be tested. Conversely, it is also not impossible that elevated Akt levels causally underlie the altered distribution of APPL1 endosomes. What is the effect of Akt inhibition on APPL1 distribution in delta_alphaAD cells?
3. The observation that treatment of ARPE-19 cells with a GSK3beta inhibitor faciliates Tf uptake and accelerates CCP dynamics indeed suggests a possible physiological role of Akt signaling in CME. Since this seems a key point it would be important to confirm this in at least one other cell line.
Translating the authors' model into cell physiology this would mean that signaling via PI3K-Akt, i.e. downstream of RTKs alters CCP dynamics in a similar manner. Does stimulation of cells with EGF or insulin alter CCP dynamics and boost Tf uptake in the predicted manner? Such data would be an important but essential confirmation of the physiological significance of the reported findings.
3. The authors speculate based on indirect assessment of pAkt and pGSK3 levels that differential phosphorylation of dynamin 1 underlies maintanence of CME in delta_alphaAD cells. If this was correct one would expect that effects of PI3K or GSK3beta inhibition can be overcome by expression of a non-phosphorylatable dynamin 1 mutant? Conversely, they should be mimicked by phosphomimetic dynamin 1.
6. Quantifications and statistics: Some of the data appear preliminary. For example, it is unclear how many cells were analyzed for the data shown in fig. 1E and no statistics are provided. More importantly: Are the changes in pGSK3 and pAkt levels in delta_alphaAD cells statistically different from those of the corresponding WT cells? Lastly, the authors claim on p.8 that the effects of GSK3beta inhibition are "still evident in Dyn2 KD cells", although no statistical comparison between these two samples is provided in fig. 5C .
Minor point:
7. The references appear biased towards selfd-citations. For example, the recent work by Zerial and colleagues on the interplay between endosomal traffic and signaling should be cited.
Referee #2:
The study by Reis and colleagues addresses the effect of overexpressing a truncated version of alpha-adaptin (lacking the appendage domain that binds a number of endocytic accessory proteins).
The authors suggest that expression of this mutant dysregulates clathrin-mediated endocytosis, alters endosomal maturation and acidification, and perturbs intracellular signaling pathways. Concerns regarding the physiological relevance of these effects are alleviated in part by recent work from the Pelkmans group, which found that inhibition of GSK3beta enhances clathrin-mediated endocytosis in HeLa cells, consistent with the findings presented in the work under review. The advance here is the connection to dynamin 1, which is nicely presented. Nonetheless, some additional concerns are noted, which should be addressed prior to further consideration.
1. Although the authors confirm that transferrin receptor uptake is efficient in cells overexpressing the mutant form of alpha-adaptin, can the authors comment on the study state levels of the receptor present on the surface of control vs. the overexpressing cells? In other words, the authors should rule out the possibility that differences in the level of cell surface transferrin receptor may account for some of the differences observed in labeled transferrin uptake/trafficking assays. 2. How is the morphology of endosomes affected when overexpressing the mutant form of alphaadaptin (e.g., at the ultrastructural level)? Is the mutant alpha adaptin associated with endosomes? If not, can the authors measure its dynamics at clathrin coated pits? A mechanistic understanding of how this mutant disrupts intracellular trafficking is entirely lacking -ideally this could be addressed in a revision. 3. The effect of expressing a form of Dyn1 that cannot be phosphorylated by GSK3beta -Dyn1(S774A) -should be investigated in control cells, as opposed to complete reliance on siRNAmediated depletion of Dyn1, which could have off target effects. Based on the authors' conclusion, this form of Dyn1 should be active, increase clathrin-mediated endocytosis, and act in the presence of GSK3beta inhibitors.
1st Revision -authors' response 26 May 2015
We thank the editor and reviewers for their overall positive response to our paper reporting the unexpected discovery that dynamin-1 can be activated in non-neuronal cells for more rapid and dysregulated clathrin-mediated endocytosis.
As referee 1 states, this is a "surprising observation". As such, our findings generate many new questions and point to new lines of experimentation, which we believe are beyond the scope of this initial report. Thus, in response to the referees concerns we have chosen to address the main issues needed to strengthen our conclusions, so that others and we are motivated to pursue these "surprising observations".
A major and important addition is the extension of this discovery to another cell line, H1299 non-small cell lung cancer cells, and use of CRISPR-Cas9n knockout technology and reconstitution to establish that dynamin-1, through phosphorylation of S774, is indeed the target for Akt-dependent regulation of CME.
We have added an additional author, Saipraveen Srinivasin, who was responsible for the generation and characterization of these cells.
Specific responses to referees:
Referee 1:
Reis et al report here on the surprising observation that Akt-GSK3beta signaling can activate dynamin 1 in cells lacking the AP-2 alpha ear domain (delta_alphaAD). These have previously been shown to display increased rates of CCP nucleation and fast maturation of a subset of CCPs that compensate for an overall defect in the formation of productive CCPs. The authors report here that dysregulated CME in delta_alphaAD cells is linked to alterations the early endosomal system leading to hyperactive Akt, which via inhibition of GSK3beta appears to release dynamin 1 from phosphoinhibition. Delta_alphaAD cells accumulate APPL1 endosomes close to the plasma membrane resulting in defects in early endosome fusion. Furthermore, the levels of pAkt and its downstream target pGSK3 are upregulated in these cells, a phenotype that depends on the presence of APPL1, a known regulator of endosomal Akt signaling. Reis et al therefore hypothesize that altered Akt-GSK3 affects downstream endocytic or endosomal components, in particular hypophosphorylation and therefore activation of dynamin 1. Finally, it is shown that Tf-CME in wild-type ARPE-19 cells is faciliated by inhibition of GSK3beta, and, importantly this treatment mimicks increased rates of CCP nucleation and altered CCP dynamics observed in delta_alphaAD cells, suggesting that the Akt-GSK3beta pathway may be physiologically regulate CME.
This Ms reveals a potentially interesting connection between CME and Akt signalling that seems worthy of publication in The EMBO J provided my major concerns below have been addressed appropriately
We thank the referee for their accurate summary of our findings and his/her appreciation of their significance. We have addressed those concerns that are necessary to strengthen our conclusions regarding the unexpected connection between Akt signaling, Dyn1 activation and CME in non-neuronal cells.
1. A key conclusion from this work is that dynamin 1 can be activated to support CME in non-neuronal cells; yet, CME remains sensitive to Dyn2 depletion. This is perplexing as the authors note themselves. So, do Dyn1 and 2 operate at the same CCPs and is OE of Dyn2 able to rescue defective CME in Dyn1-depleted delta_alphaAD cells?
We agree that this interesting observation requires further investigation. Because overexpression of the dynamin isoforms might alter their differential districutions, it is important to address this issue at endogenous levels of expression. With this in mind, we first tried the 'easy' experiment to localize dynamin-1 and dynamin-2 by immunefluorescence using isoform specific antibodies. Several antibodies detect dynamin-1 and -2 specifically by western blot but, unfortunately, did not work well for immunofluorescence studies. Thus, we plan to pursue this question in the future through genome-editing of both Dyn1 and Dyn2 in the same cells to determine a) if they are at the same or different CCPs, and/or b) if Dyn1 vs Dyn2 exhibit different dynamics at CCPs. For the same reasons, we do not believe that overexpressing Dyn2 in mutant ΔαAD cells would be physiologically relevant or meaningful and hence have not attempted it. Instead we are focusing our future efforts on dissecting the functional differences between Dyn1 and Dyn2 in normal cells.
2. How do altered distribution of APPL1 endosomes and endosomal defects relate to CME? If indeed altered APPL1 distribution and recruitment and overactivation of Akt is the primary problem then depletion of APPL1 in delta-alphaAD cells should impair CME of Tf, similar to Akt inhibition. This should be tested.
Thank you for the suggestion. We have done this experiment and, as predicted, the depletion of APPL1 impairs Tfn CME in the ΔαAD cells, but not in FL cells. These findings are included in the revised manuscript (new Figure 6A) .
Conversely, it is also not impossible that elevated Akt levels causally underlie the altered distribution of APPL1 endosomes. What is the effect of Akt inhibition on APPL1 distribution in delta_alphaAD cells?
We have followed the referee's suggestion and performed this experiment, as well as examining the effect of GSK3β inhibition on the accumulation of APPL1 early endocytic intermediates (see new Figure 6B , C). The results strengthen our conclusions regarding a two-way crosstalk between signaling (along the Akt-GSK3β access) and early endocytic trafficking. In ΔαAD cells, where Akt is highly activated and APPL1 endosomes accumulate, the inhibition of Akt results in reduced levels of APPL1 endosomes. In contrast, in FL control cells, the inhibition of GSK3β, which would activate Dyn1 and trigger dysregulated CME, APPL1 endosomes accumulate.
The observation that treatment of ARPE-19 cells with a GSK3beta inhibitor facilitates
Tf uptake and accelerates CCP dynamics indeed suggests a possible physiological role of Akt signaling in CME. Since this seems a key point it would be important to confirm this in at least one other cell line.
We agree with the referee that additional evidence for physiological relevance would strengthen our paper. As now clearly discussed in the revised text, we were struck by the observation that Dyn1 is up-regulated and/or Akt is activated in many cancers. The clear implication is that cancer cells may trigger dysregulated CME that would alter signaling from e.g. EGFR. Consistent with this and as we had indicated in our discussion Liberali et al (Cell, 2014) had identified both Akt and GSK3β as top hits for regulators of CME in HeLa cells. Thus, we have tested this possibility using the non-small cell lung cancer cell line, H1299 and present the data here (new Figure 8A and B). As our model would predict, CME in H1299 cancer cells is sensitive to both Dyn1 siRNA knockdown and Akt inhibition.
More importantly, we have also used CRISPR technology to knockout Dyn1 in H1299 cells and then rescued the knockout phenotype with either low expression of WT Dyn1-EGFP or S774A-Dyn1-EGFP (new Figure 8C and D) . These results demonstrate that Tfn uptake via CME in H1299 cells is inhibited by ~40% in H1299 Dyn1 KO cells (as shown using siRNA) and that CME in H1299 cells, but not in H1299 KO cells is sensitive to Akt inhibition (confirming that the effect of Akt on CME is Dyn1 dependent). Both of these effects can be fully rescued by reconstitution with WT-Dyn1-EGFP. Our model, that S774 phosphorylation alone can be responsible to inhibiting Dyn1 activity is oversimplified, as S774A-Dyn1-EGFP is able to rescue Tfn uptake to control levels, but not beyond (similar to the results obtained with GSK3β inhibition in H1299 cells). However, that S774A phosphorylation is the target of Akt is supported by our data, as CME in the S774A cells is no longer sensitive to Akt inhibition. These results strengthen our overall conclusions and have been included in the revised manuscript.
The reviewer is correct that this is indeed an intriguing implication from our studies that warrants further investigation. We and others have in the distant past shown that EGF treatment does not enhance Tfn uptake. However, it is possible that different cargo molecules, in particular other signaling receptors, might selectively recruit Dyn1 to their CCPs. We plan to test this possibility in future studies.
3. The authors speculate based on indirect assessment of pAkt and pGSK3 levels that differential phosphorylation of dynamin 1 underlies maintenance of CME in delta_alphaAD cells. If this was correct one would expect that effects of PI3K or GSK3beta inhibition can be overcome by expression of a non-phosphorylatable dynamin 1 mutant? Conversely, they should be mimicked by phosphomimetic dynamin 1.
See answer to point 3 above. While we have chosen to address this issue in H1299 NSCLC cells rather than the αΔAD cells, as predicted by the referee the non-phosphorylatable form of Dyn1 is indeed no longer sensitive to Akt inhibition. Again, we have included this finding (new Figure 8D) as it strengthens our conclusions.
Thank you for raising this point. We have included significance measurements and statistics as requested.
Referee 2:
The study by Reis and colleagues addresses the effect of overexpressing a truncated version of alpha-adaptin (lacking the appendage domain that binds a number of endocytic accessory proteins). The authors suggest that expression of this mutant dysregulates clathrin-mediated endocytosis, alters endosomal maturation and acidification, and perturbs intracellular signaling pathways. Concerns regarding the physiological relevance of these effects are alleviated in part by recent work from the Pelkmans group, which found that inhibition of GSK3beta enhances clathrin-mediated endocytosis in HeLa cells, consistent with the findings presented in the work under review. The advance here is the connection to dynamin 1, which is nicely presented. Nonetheless, some additional concerns are noted, which should be addressed prior to further consideration.
We agree with the referee that while our analysis of the ΔαAD cells led to the discovery of the regulation of Dyn1 downstream of Akt and GSK3β, it is critical to establish that this signaling cascade operates in a more physiological context. We also appreciate the referee's awareness of the Liberali/Pelkmans study that independently identified these kinases as key regulators of CME in HeLa cells, although our work establish Dyn1 as a specific target for these effects. As described below and also in response to referee 1, we have added new data to strengthen our conclusions.
1. Although the authors confirm that transferrin receptor uptake is efficient in cells overexpressing the mutant form of alpha-adaptin, can the authors comment on the study state levels of the receptor present on the surface of control vs. the overexpressing cells? In other words, the authors should rule out the possibility that differences in the level of cell surface transferrin receptor may account for some of the differences observed in labeled transferrin uptake/trafficking assays.
Thank you for raising this point. The referee is correct that changes in the level of surface TfnR could account for differences in CME. Thus, in all of our experiments we measured CME relative to surface levels. We previously ruled out that changes in TfnR levels could contribute to the differences we saw, as we have not detected any significant changes in TfnR surface levels in neither WT, FL or AD cells. We have now included our data regarding total surface TfnR in the new Figure S1B .
2. How is the morphology of endosomes affected when overexpressing the mutant form of alpha-adaptin (e.g., at the ultrastructural level)? Is the mutant alpha adaptin associated with endosomes? If not, can the authors measure its dynamics at clathrin coated pits? A mechanistic understanding of how this mutant disrupts intracellular trafficking is entirely lacking -ideally this could be addressed in a revision.
This is an interesting question regarding the products of CME in the mutant cells, which we believe is beyond the scope of this paper. Our analysis of the mutant cells simply revealed the unexpected activation of Dyn1, and caused us to shift the focus of this paper towards this unexpected discovery by establishing that this mechanism also occurs in other cell lines, such as WT ARPE-19 and H1299 cells. We have however used immunofluorescence to examine α-adaptin localization and did not detect any significant AP2 associated with endosomes. Also, by making use of CLC-EGFP using our detection of early endosomes (shown in Fig 1) , we have looked at the degree of colocalization between clathrincoated structures (CCS) and APPL1 or EEA1 (see Figure  to left ). Again, we have not detected any increase in colocalization between CCS and early endosomes (APPL1 or EEA1). In future studies we plan to pursue the mechanism by which the mutant-and Dyn1 activationalters early endocytic trafficking.
3. The effect of expressing a form of Dyn1 that cannot be phosphorylated by GSK3beta -Dyn1(S774A) -should be investigated in control cells, as opposed to complete reliance on siRNA-mediated depletion of Dyn1, which could have off target effects. Based on the authors' conclusion, this form of Dyn1 should be active, increase clathrin-mediated endocytosis, and act in the presence of GSK3beta inhibitors.
We agree that these experiments would greatly strengthen our conclusions. Hence we have used CRISPR-Cas9n technology to knockout Dyn1 and to reconstitute these cells with WT-Dyn1-EGFP and S774A-Dyn1-EGFP (see new Figure 8C and D panels). The referee is also correct in his/her predictions. Although WT and S774A mutant are active and efficiently reestablish CME in Dyn1 KO cells, we did not detect a further increase in the rate of CME in S774 cells, similarly to the condition where we inhibited GSK3B ( Figure 8B ). We think that other phosphorylation sites, for example the second site needed to GSK3β recognition, might also be inhibitory). Importantly, and as predicted, the S774A mutant is no longer sensitive to Akt inhibition. Thank you for submitting your revised manuscript for our consideration. Your manuscript has now been seen once more by the original referees (see comments below), and I am happy to inform you that they both appreciate the introduced changes. I am thus happy to accept
Referee Figure 1: Calthrin does not colocalize with early endosomes

